Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 18/20 | 0.70 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.64 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.64 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6008820 | 0.92 | ALOX5 (0.68) | ALOX5ALOX12PTGS1PTGS2MTNR1A | |
| SCHEMBL9729587 | 0.88 | ALOX5 (0.68) | ALOX5ALOX12PTGS1PTGS2MTNR1A | |
| SCHEMBL9730193 | 0.86 | ALOX5 (0.85) | ALOX5ALOX12PTGS1PTGS2MTNR1A | |
| SCHEMBL9729734 | 0.82 | ALOX5 (1.00) | ALOX5ALOX12PTGS1PTGS2 | |
| SCHEMBL9729495 | 0.81 | ALOX5 (0.61) | ALOX5ALOX12PTGS1PTGS2MTNR1A | |
| SCHEMBL9729520 | 0.81 | ALOX5 (1.00) | ALOX5ALOX12PTGS1PTGS2 | |
| SCHEMBL9730598 | 0.80 | ALOX5 (1.00) | ALOX5ALOX12PTGS1PTGS2 | |
| Hydrochloric Acid SCHEMBL9731115 | 0.80 | ALOX5 (0.60) | ALOX5ALOX12PTGS1PTGS2MTNR1A | |
| SCHEMBL9729579 | 0.80 | ALOX5 (1.00) | ALOX5ALOX12PTGS1PTGS2 | |
| SCHEMBL9729757 | 0.80 | ALOX5 (0.72) | ALOX5ALOX12PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5155130-A | Lipoxygenase inhibitors | CIBA-GEIGY CORPORATION (US) | 1992-10-13 | — | — | US | disclosed |
| EP-0412939-A2 | Certain benzopyran and benzothiopyran derivatives | CIBA-GEIGY AG (CH) | 1991-02-13 | — | — | EP | disclosed |